Objective  To evaluate the rationality of off-label use of chlorpromazine through evidence-based medicine, so as to provide evidence for promoting clinical rational drug use.

Methods  The prescriptions of chlorpromazine used in outpatient of hospital prescription cooperative program in 2017-2019 were pooled to determine whether it was off-indication based on the drug instructions, and to evaluate its rationality according to evidence-based evidence and poly-pharmacy.

Results  A total of 9 620 prescriptions of chlorpromazine were analyzed, including 4 388 off-label prescriptions, the incidence of off-label drug use was 45.61%, and the rate of off-label drug use was 20.45% in poly-pharmacy. Off-indications mainly include bronchial and other respiratory diseases, mental disorders, mental retardation, epilepsy, bipolar disorder etc.

Conclusion  The off-label use of chlorpromazine is common, part of them are reasonable, but there are still drug risks. Medical institutions should standardize the management of off-label use and promote the rational clinical use of chlorpromazine.

1.Boyd-Kimball D, Gonczy K, Lewis B, et al. Classics in chemical neuroscience: chlorpromazine[J]. ACS Chem Neurosci, 2019, 10(1): 79-88. DOI: 10.1021/acschemneuro.8b00258.

2.郭姗姗, 史卫忠, 李草, 等. A型肉毒毒素超说明书用药分析与循证评价[J]. 中南药学, 2020, 18(8): 1396-1401. [Guo SS, Shi WZ, Li C, et al. Evidence-based evaluation of off-label use of botulinum toxin type A[J]. Central South Pharmacy, 2020, 18(8): 1396-1401.] DOI: 10.7539/j.issn.1672-2981.2020.08.023.

3.伍俊妍, 邱凯锋, 曾英彤, 等. 广东省药学会超说明书用药规范管理工作成果写入《医师法》[J]. 今日药学, 2021, 31(12): 886-888. [Wu JY, Qiu KF, Zeng YT, et al. Achievement of off-label drug use management by the Guangdong Pharmaceutical Association written into the China Physicians Law[J]. Pharmacy Today, 2021, 31(12): 886-888.] DOI: 10.12048/j.issn.1674-229X.2021.12.002.

4.张沫, 周洋, 石秀锦, 等. 2015-2020年我国96家医院口服抗凝药物使用情况分析[J]. 临床药物治疗杂志, 2022, 20(8): 44-49. [Zhang M, Zhou Y, Shi XF, et al. Utilization analysis of oral anticoagulant drugs in 96 hospitals from 2015 to 2020[J]. Clinical Medication Journal,2022, 20(8): 44-49.] DOI: 10.3969/j.issn.1672- 3384.2022.08.009.

5.杨敏, 劳海燕, 曾英彤. 医疗机构超药品说明书用药管理专家共识[J]. 中国现代应用药学, 2017, 34(3): 436-438. [Yang M, Lao HY, Zeng YT. Expert consensus on drug use management beyond drug instructions in medical institutions [J]. Chinese Journal of Modern Applied Pharmacy, 2017, 34 (3):436-438.] DOI: 10.13748/j.cnki.issn1007-7693.2017.03.031.

6.薛朝军, 靳会欣, 安静, 等. 对某院超说明书用药申请进行循证医学分析[J].中国医院药学杂志, 2018, 38(14): 1554-1557. [Xue CJ, Jin HX, An J, et al. Evidence-based medical analysis for the application of off-label drug use in a hospital[J]. Chinese Journal of Hospital Pharmacy,2018,38(14): 1554-1557.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.14.25.

7.Smith DJ, Whitham EA, Ghaemi SN. Bipolar disorder[J]. Handb Clin Neurol, 2012, 106: 251-263. DOI: 10.1016/B978-0-444-52002-9.00015-2.

8.Conus P, Berk M, Cotton SM, et al. Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: an 8-week randomised controlled trial[J]. Eur Psychiatry, 2015, 30(8): 975-982. DOI: 10.1016/j.eurpsy. 2015.09.009.

9.Modak T, Kumar S, Pal A, et al. Chlorpromazine as prophylaxis for bipolar disorder with treatment and electroconvulsivetherapy-refractory mania: old horse, new trick[J]. Indian J Psychol Med, 2017, 39(4): 539-541. DOI: 10.4103/0253-7176.211759.

10.Amure BO, Ginsburg M. Effects of chlorpromazine and bromolysergic acid diethylamide on gastric secretion of acid inducedby histamine in rats[J]. Brit J Pharmacol, 1964, 22(3): 520-526. DOI: 10.1111/j.1476-5381.1964.tb01706.x.

11.Stuart-Harris R, Buckman R, Starke I, et al. Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy[J]. Postgrad Med J, 1983, 59(694): 500-503. DOI: 10.1136/pgmj.59.694.500.

12.Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection[J]. Antimicrob Agents Ch, 2014, 58(8): 4885-4893. DOI: 10.1128/AAC.03036-14.

13.Stip E. Psychiatry and COVID-19: the role of chlorpromazine[J]. Can J Psychiatry, 2020, 65(10): 739-740. DOI: 10.1177/0706743720934997.

14.Blessing WW, Blessing EM, Mohammed M, et al. Clozapine, chlorpromazine and risperidone dose-dependently reduce emotional hyperthermia, a biological marker of salience[J]. Psychopharmacology (Berl), 2017, 234(21): 3259-3269. DOI: 10.1007/s00213-017-4710-x.

15.Dundee JW, Mesham PR, Scott WE. Chlorpromazine and the production of hypothermia[J]. Anesthesia, 1954, 9(4): 296-302. DOI: 10.1111/j.1365-2044.1954.tb01927.x.

16.常琳, 王小姗. 中国癫痫流行病学调查研究进展[J]. 国际神经病学神经外科学杂志, 2012, 39(2): 161-164. [Chang L, Wang XS. Progress in epidemiological investigation of epilepsy in China[J]. Journal of International Neurology and Neurosurgery, 2012, 39(2): 161-164.] https://d.wanfangdata.com.cn/periodical/gwyx-sjbxsjwkxfc201202014.

17.Rettig JH. Chlorpromazine and mysoline in the control of convulsive epilepsy in mentally deficient patients[J]. J Nerv Ment Dis, 1956, 124(6): 607-611. DOI: 10.1097/00005053-195612000-00008.

18.Fabisch W. The effect of chlorpromazine on the electroen-cephalogram of epileptic patients[J]. J Neurol Neurosurg Psychiat, 1957, 20(3): 185-190. DOI: 10.1136/jnnp.20.3.185.

19.Barsa JA, Kline NS. Depression treated with chlorpromazine and promethazine[J]. Am J Psychiatry, 1957, 113(8): 744-745. DOI: 10.1176/ajp.113.8.744.

20.Isbister GK, Balit CR, Kilham HA. Antipsychotic poisoning in young children: a systematic review[J]. Drug Safety, 2005, 28(11): 1029-1044. DOI: 10.2165/00002018-200528110-00004.

21.Tatlow W, Fisher C, Dobkin A. The clinical effects of chlorpromazine on dyskinesia[J]. Can Med Assoc J, 1954, 71(4): 380-381. https://pubmed.ncbi.nlm.nih.gov/13199744/.

22.Canoso RT, Romero JA, Yunis EJ. Immunogenetic markers in chlorpromazine-induced tardive dyskinesia[J]. J Neuroimmunol, 1986, 12(3): 247-252. DOI: 10.1016/s0165-5728(86)80008-x.

23.Alfredsson G, Härnryd C, Wiesel FA. Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients-relationship to drug concentrations[J]. Psychopharmacology, 1985, 85(1): 8-13.DOI: 10.1007/BF00427315.

24.Terndrup TE, Dire DJ, Madden CM, et al. Comparison of intramuscular meperidine and promethazine with and without chlorpromazine: a randomized, prospective, double-blind trial[J]. Ann Emerg Med, 1993, 22: 206-211.DOI: 10.1016/s0196-0644(05)80204-5.

25.Yamamoto J, Kline FM, Burgoyne RW. The treatment of severe anxiety in outpatients: a controlled study comparing chlordiazepoxide and chlorpromazine[J]. Psychosomatics, 1973, 14(1): 46-51. DOI: 10.1016/S0033-3182(73) 71374-8.

26.Fujii R, Hasuo H, Sakuma H, et al. The efficacy and safety of intravenous chlorpromazine treatment for sleep disturbance in patients with incurable cancer, with oral administration difficulty: a 1-week, prospective observational study[J]. Ann Palliat Med, 2021, 10(8): 8547-8556. DOI: 10.21037/apm-21-948.

27.Reiss F. Psoriasis and stress[J]. Dermatology, 1956, 113(2): 71-78. DOI: 10.1159/000256166.

28.杨燕, 何文富, 肖林. 精神专科医院奥氮平超说明书用药门诊处方调查分析[J]. 临床药物治疗杂志, 2018, 16(6): 86-88. [Yang Y, He WF, Xiao L. Investigation and analysis of off-label usage of olanzapine prescriptions for out-patients in psychiatric hospital Department of pharmacy[J]. Clinical Medication Journal, 2018, 16(6): 86-88.] DOI: 10.3969/j.issn.1672-3384.2018.06.021.

29.王颖，谭湘萍，司徒冰. 我院超说明书用药的分级管理研究[J]. 中国药房, 2017, 28(10): 1306-1310. [Wang Y, Tan XP, Situ B. Study on the classification management of off-label drug use in our hospital[J]. China Pharmacy, 2017, 28(10): 1306-1310.] DOI: 10.6039/j.issn.1001- 0408.2017.10.03.